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ABSTRACT
Objectives: Crohn disease is a chronic inflammatory bowel
disorder that is caused by environmental and genetic factors.
Mutations in the CARD15 gene have been recently identified to
be associated with the disease. Until now no genetic study has
focused directly on a pediatric population.
Methods: The authors sequenced all 12 exons of the CARD15
gene in 55 pediatric patients with Crohn disease from Saxony.
Their average age at onset was 11.2 years (1–17.5 years). The
authors also evaluated the genotype-phenotype relationship in
the patients.
Results: Fourteen different polymorphic and/or disease-related
nucleotide alterations have been identified in the patients.
Sixty-five percent of their genomic DNA samples harbored at
least one of six mutations within the CARD15 gene, which
previously has been identified as being associated with Crohn
disease. The authors found that the cytosine insertion mutation
3020insC was significantly more common in their pediatric
population than in patients with Crohn disease (26% versus
11% of the alleles) whose results were reported in the literature.
The genotype–phenotype analysis showed that the authors’ pa-
tients with at least one of the six CARD15 disease-associated
mutations had a high risk of inflammation located in the ter-
minal ileum and ascending colon. In 10 of 19 patients with two
mutations, intestinal resection surgery was necessary because
of stricturing.
Conclusions: In the authors’ pediatric patients, the genetic
influence on Crohn disease was more pronounced than that
reported in any other study, and it strongly affected the
clinical phenotype. JPGN 37:492–497, 2003. Key Words:
Crohn disease—CARD15—NOD2— Mutation—Stricturing—
Surgery. © 2003 Lippincott Williams & Wilkins, Inc.
INTRODUCTION
Crohn disease (CD [OMIM 266600]) is a chronic re-
lapsing intestinal inflammatory disorder. It may involve
any part of the gastrointestinal tract but is most fre-
quently located in the terminal ileum and colon. CD is
primarily a disease of adolescence and young adulthood,
with peak incidence occurring between 15 and 30 years
of age (1). The incidence of CD has been steadily in-
creasing in the pediatric age group (2).
With the use of genome-wide linkage analyses and
positional cloning methods, one gene on chromosome 16
(16q12) was identified to be associated with CD (3,4);
the gene was named NOD2, but later the name was
changed to CARD15 (5). It is a member of the Apaf-
1/Ced4 superfamily, expressed in monocytes and impor-
tant for inflammatory signal transduction. The CARD15
gene product can activate the transcription factor NF-B
upon stimulation with the bacterial cell membrane com-
ponent lipopolysaccharide (6). A disregulation of this
process caused by alterations in the CARD15 gene has
been proposed as an important factor that contributes to
CD. The normal gene encodes a protein (Fig. 1) that
contains two N-terminal CARDs (caspase recruitment
domain), a centrally located NBD (nucleotide-binding
oligomerization domain), and 10 C-terminal LRRs
(leucine-rich repeats) (7).
LRRs are regarded as primary sensors of the innate
immune system (8). In CARD15, it is required to sense
lipopolysaccharide and to activate an NF-B signaling
pathway (9). NF-B regulates apoptosis and promotes
proinflammatory gene expression. Many patients with
CD have the insertion of a cytosine (3020insC), which
leads to an early stop codon and the deletion of 33 amino
acids at the C terminal end of the leucine-rich region.
The mutation might increase NF-B translocation and
thereby elicit spontaneous inflammation. However, the
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mechanism by which the mutations affect the pathway of
apoptosis or NF-B activity remains unknown (8).
It has been suggested that genetic factors are particu-
larly important in early onset inflammatory bowel dis-
ease (IBD) (5), but until now, no large groups compris-
ing only children have been studied. The purpose of our
study was to examine the CARD15 genotype in pediatric
patients and to identify associations with their pheno-
types.
MATERIALS AND METHODS
From January 1, 1982, to March 1, 2002, in the Pediatric
Clinic of the Technical University of Dresden, 108 patients
younger than 18 who had diagnoses of IBD agreed to partici-
pate in the genetic study. Fifty-five of them had CD. Venous
blood samples were obtained from these patients (all parents
gave written informed consent) and from 101 healthy control
subjects with the same ethnic background; the control subject
blood samples came from a German blood bank in Saxony. All
patients were seen by two gastroenterologists (J. Henker, U.
Winkler), and all medical records were reviewed by two inves-
tigators (A. Thürigen, L. Sun). The diagnosis of CD was con-
firmed by clinical, radiologic, endoscopic, and histologic analy-
sis according to the criteria of Lennard-Jones (10). We ex-
cluded patients in cases of uncertainty or indeterminate colitis.
Genotype analysis
Purification of genomic DNA
For isolation of DNA the Invisorb® Spin Blood Kit (Berlin-
Buch, Germany) was used according to the protocol provided.
Polymerase chain reaction conditions
A pair of primers was designed for each exon of CARD15
(GenBank accession number AF178930) except for exons 2, 4,
5, and 6. For exon 2, two overlapping fragments were ampli-
fied; and for exon 4, four overlapping fragments were ampli-
fied; exon 5 and 6 used the same amplified fragment (Table 1).
Thermostable DNA polymerase, Ampli Taq Gold, and 10 ×
buffer containing 15 mM MgCl2 were purchased from Perkin
Elmer (Weiterstadt, Germany). Five microliters of buffer were
mixed with 2.5 L dioxyribonucleotides (dNTPs) (10 mM of
each), 2.5 L of each primer (250 ng), 5 L genomic DNA
solution, 0.5 L polymerase (2.5 U), and 37 L double-
distilled H2O (ddH2O). The cycle program included 10 minutes
at 94°C to denature the DNA, 35 cycles of 45 seconds at 94°C,
45 seconds at annealing temperature adapted to the primer pairs
(54°C–62°C), 90 seconds at 72°C, and 5 minutes final exten-
sion at 72°C. Synthesis of appropriately sized polymerase chain
reaction (PCR) products was confirmed by agarose gel electro-
phoresis. The PCR product was cleaned from primers and other
low–molecular-weight compounds by Microcon-50 filter de-
vices (Amicon, Witten, Germany).
Cycle sequencing
The BigDye Terminator Cycle Sequencing Reaction was
purchased from Perkin Elmer to determine mutations in the
CARD15 gene according to the protocol provided. Briefly, af-
ter mixing 0.5 L of the described PCR products (approxi-
mately 50 ng DNA) with 1.0 L primer (50 ng), 4 L termi-
nator ready reaction mix (containing Mg2+, pyrophosphatase,
and polymerase), and ddH2O to a final reaction volume of 20
L, the following cycle conditions were applied: ×25, 96°C for
30 seconds, at annealing temperature adapted to the primer
FIG. 1. Distribution of the nonconservative mutations along CARD15. Note: the three main disease-associated mutations are marked
with an asterisk, the remaining mutations in boldface are likely to be disease associated, and P268S is not disease associated (15).
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pairs (54°C–62°C) for 15 seconds, and 60°C for 4 minutes, 4°C
forever (Trio Thermoblock, Biometra, Göttingen, Germany).
The sequence was determined using the ABI 310 automatic
sequencer (Applied Biosystems, Foster City, CA, USA). The
whole sequence of the coding regions, including adjacent in-
tronic regions, was determined in each patient and control sub-
ject. The DNA sequence of each patient was compared with the
published CARD15 gene sequence (GenBank accession num-
ber AF178930) and the sequence of a healthy control subject
using the ABI 310 sequence navigator software, version 1.0.1
(Applied Biosystems).
Phenotype analysis
The phenotypic classification was based on disease localiza-
tion and behavior. Family history was defined as having at least
one first- or second-degree relative with CD. Localization was
determined by radiologic, histologic, or endoscopic examina-
tion. It was divided into three categories: upper gastrointestinal
tract (including jejunum or upper ileum), ileocolonic (terminal
ileum or terminal ileum and ascending colon), and colon (trans-
verse colon, descending colon, sigmoid, or rectum). Complica-
tions included stricturing and fistulizing disease. Extraintestinal
manifestations included eye, skin, joint, lung, hair, bone, and
liver involvement (e.g., arthritis, arthralgia, uveitis, erythema
nodosum). Surgical intervention was defined as any operative
procedure for fistulizing or perforating disease, intractable dis-
ease, and the need for gut resection.
Statistics
Data were evaluated with the SPSS 10.0 and Epi Info 5.0
(SPSS Inc., Chicago, IL, USA, and WHO, Gent, Switzerland)
software. The following tests were performed to analyze pos-
sible associations with mutations: univariate logistic regression
for age at onset of CD, 2 method (cross-table analyses) and
Fisher exact test for family history, disease localization, com-
plications, extraintestinal manifestations, and intestinal resec-
tion. 2 testing was also used to compare the published muta-
tion frequency with the respective frequency in our patients and




We have sequenced all 12 exons of the CARD15 gene
(including 80–200 bp of the adjacent introns) in 55 pa-
tients with CD and exon 11 in 101 control samples from
healthy donors. Fourteen different nucleotide alterations,
as compared with the published standard sequence, were
found in the patients (Table 2). Most of them were lo-
cated in exon 4 (length of 1816 bp); no variations were
seen in exon 3 (106 bp), exon 5 (84 bp), exon 6 (86 bp),
exon 7 (84 bp), or exon 12 (70 bp). Of the 14 sequence
alterations, 3 occurred in the noncoding regions (UTR)
and were even more common than the standard se-
quence. Except for the cytosine insertion mutation
(3020insC), the variants resulted in single base-pair sub-
stitutions. Of these, eight were caused by transition-type
changes (5 G→A, 5 C→T). Of the 11 mutations in the
coding regions, three (S178S, R459R, R587R) were si-
lent, one was conservative (V955I), and the other seven
were all nonconservative missense mutations. However,
one of these, P268S, was not considered to cause CD
because of its tight linkage disequilibrium with other
mutations (3,5).
The allele frequencies of the three main disease-
associated mutations, R702W, G908R and 3020insC,
were calculated to be 14%, 5%, and 26%, respectively.
The frequencies for the other three missense mutations,
R703C, E778K, V793M, which are likely to be disease
associated (5), were all 2% (two patients each carried one
of the mutations). Nine patients were homozygous for
3020insC, 2 for R702W, and 1 for G908R, but no patient
was homozygous for one of the three rare mutations. In
addition, 7 patients had two different mutations (Table
3); 17 had one mutation; and 19 of the pediatric patients
with CD had none of the six mutations.
We confirmed that 3020insC in exon 11 was signifi-
cantly more common among patients with CD (allele





1 TTG TGC CAG AAT TGC TTG GAA TT GCC CTG GAG TGG TTC TCA GCT 513
2a GGG GAG CTT GGA TTG GGT AAT GCC GGT GAC TCT GCA GGT CT 484
2b GCC AGC CTC TCT CCC ACT T TAG CCA GGG TAA CAG AGT GAG AA 531
3 TTG GAT GCA TGC GTT CAA TTC CGG GGT GGT GCT AGC CTT AA 451
4a GGC TCT CCT ATC CCT TCA GTT AT AAG AGC AGG GTC TGG ACA GAG 689
4b GCA GGG CAA GAC TTC CAG GAA TT CAG GCC CCA CAG AGC CAG TCT 723
4c GTG TCC AAA TGC CAC CAG GAA CTG T CCA GAC ACC AGC GGG CAC AG 661
4d TTC CTG GCA GGG CTG TTG T GCT GGG CCC AGA CTT CTA GAG 530
5,6 GCT GGC ACT TCA GGG ATG AAT GAA CAG TGC CAG GCC AAG ACC AGA TC 574
7 CCT CCC GGG CAG GTC TTC AAT GGG GCC TCC TGG CTG AAG AGT 292
8 CTG CCC CTC TGG CTG GGA CTG TGG CCC CAG CTC CTC CCT CTT 258
9 CCA CGA ATT TTG CCC TCC ATA G GGC CAG GGG ATC AAC AGA GAT 230
10 AAT CCC CAC AAC GTA CTT TAT CT AGA CCA AGG CAA GCT GTT CTA 365
11 CAT TGG GAA TCT CAG ACA TGA G GAA GGG ATC CTC AAA ATT CTG 336
12 CTG CAG CTG GGC CAG AGA GTC AAG AGG CTG CCA ACA CAT GTC AC 286
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frequency 26%) than among healthy control subjects
(2%), (P < 0.00000001; OR  17.72). Twenty (36%)
patients, but only 4 (4%) healthy donors, had this muta-
tion. All of these four control subjects were heterozy-
gotes, and no homozygote has ever been discovered
(Table 4).
Two of the disease-associated mutations (R702W,
R703C) detected in our patient population were located
between the nucleotide-binding oligomerization domain
and the LRR domains; the other four mutations (E778K,
V793M, G908R, 3020insC) were found within the LRR
domain (Fig. 1).
Genotype–phenotype relationship
The medical records of the 55 patients with CD were
reviewed in detail. Patient age at onset, family history,
disease localization, complications, and intestinal resec-
tion surgery were analyzed (Table 5). The average age at
onset was 11.2 years (1–17.5 years).
Patients were divided into three groups (A0, no mu-
tation; A1, one mutation; A2, two mutations). Table 5
shows the mutation distributions in the different sub-
groups of CD and the genotype–phenotype relationships.
A significant association was found between CARD15
mutations and a localization in the ileocolonic region (P
 0.005). In addition, there was a nonsignificant trend
for a higher risk to acquire CD in younger patients with
disease-associated mutations and for stricturing in pa-
tients with such mutations. The involvement of the trans-
verse colon, left colon, or rectum and extraintestinal
manifestations were relatively less common in this pa-
tient subgroup, but these trends did not reach signifi-
cance. In contrast, a positive family history, the involve-
ment of the upper gastrointestinal tract, and fistulizing
were in the same range in all groups (A0, A1, or A2). We
also evaluated a possible association between intestinal
resection surgery and CARD15 mutations. As shown in












TABLE 4. C-insertion mutation (3020insC) frequency in






−/− 35 (64%) 97 (96%)
−/+ 11 (20%) 4 (4%)
+/+ 9 (16%) 0 (0%)
Note: +: mutation, −: wildtype.
TABLE 2. CARD15 genetic variants observed in 55 patients with CD
Location and
nucleotide change Peptide change Polymorphic marker Protein domain
No (%) of variant alleles
(n  110)
No (%) of patients
(n  55)
IVS 1
5 UTR -59 G → A Unknown SNP-EX1.59 62 (56%) 41 (74%)
IVS 2
5 UTR -25 G → T Unknown SNP-I1.26 60 (55%) 41 (75%)
Exon 2
534 C → G S178S CARD2 39 (35%) 29 (53%)
Exon 4
802 C → T P268S SNP5 63 (57%) 41 (75%)
1377 C → T R459R SNP6 NBD 60 (55%) 40 (73%)
1761 T → G R587R SNP7 36 (33%) 29 (53%)
2104 C → T R702W* SNP8 15 (14%) 13 (24%)
2107 C → T R307C+ 2 (2%) 2 (4%)
2332 G → A E778K+ LRR2 2 (2%) 2 (4%)
2377 G → A V793M+ LRR2 2 (2%) 2 (4%)
Exon 8
2722 G → C G908R* SNP12 LRR6 5 (5%) 4 (7%)
Exon 9
2863 G → A V955I LRR8 12 (11%) 11 (20%)
IVS 10
5 UTR +64 A → T 85 (77%) 46 (84%)
Exon 11
3020insC 1007fs* SNP13 LRR10 29 (26%) 20 (36%)
Note: The seven nonconservative mutations are indicated in boldface, the three main disease-associated mutations are marked by an asterisk, and
the three mutations likely to be disease associated are marked by +.
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Table 5, more than half of the patients (10 of 19) with
two mutations had intestinal resections (P  0.032, A2
versus A1), indicating that this genotype (A2) could
cause a more severe clinical course of CD.
DISCUSSION
Mutations in the CARD15 gene have been found to
predispose patients to CD (3,4). Our study confirmed the
strong association of the CARD15 frameshift mutation
(3020insC) with this disorder (Table 4); 36% of our pa-
tients, but only 4% of the control blood donors, had the
mutation. The 55 pediatric patients and 101 healthy
blood donors to a Saxonian blood bank were ethnically
homogeneous because of the political situation of the
former German Democratic Republic, which highly re-
stricted the mobility of Saxons. The allele frequency
(2%) of this mutation in our control samples was the
same as in the healthy population studied by the French
group (5). They examined the genotypes of 453 patients
with CD who were recruited from a large European con-
sortium involving clinicians from Belgium, Denmark,
France, Germany, Ireland, Italy, Spain, and Sweden (5).
The average age at disease onset was 19.4 years (range,
2–56 years). We found that the 3020insC mutation was
significantly more common in our pediatric patients than
in their patient group, which had a majority of adults,
although the background populations were comparable
(26% versus 11% of the alleles, P  0.000002). Two
other mutations, R702W and G908R, had similar allele
frequencies in our pediatric patient and the patients re-
ported in the literature (Table 6). In contrast, for three
rare mutations (R703C, E778K, V793M), which were
also found in our pediatric patients, there is no firm evi-
dence they cause CD. Nevertheless, according to Lesage
et al. (5), they are likely to induce the disease.
We used direct sequencing of the CARD15 gene,
whereas other groups partially relied on screening meth-
ods (5,11,12). Although we have sequenced all coding
and adjacent intronic regions of the CARD15 genes of
our patients, we did not find a new mutation associated
with the disease. All genetic alterations found, other than
the six already known to be disease related, occurred
frequently and were located in intronic regions without
known motives (e.g., for splicing) or were silent, conser-
vative, or have already been described as a mere poly-
morphism (P268S) (3). Therefore, the number of differ-
ent disease-associated mutations in the CARD15 gene is
probably limited. Interestingly, the six disease-related
mutations (3020insC, R702W, G908R, R703C, E778K,




one sided OR 95% CI
P¶
two sidedA0 A1 A2
Age of onset 13 y (4.1–17.5 y)* 12 y (1–16 y) 11.8 y (3.6–15.6 y) 0.152† 0.991† 0.978–1.003†
Family history
+ 5 (38.5%)‡ 4 (30.8%) 4 (30.8%) 0.490§ 0.800 0.221–2.902 0.93
− 14 (33.3%) 13 (31.0%) 15 (35.7%)
Localization
UGT
+ 11 (36.7%) 9 (30.0%) 10 (33.3%)
− 8 (32.0%) 8 (32.0%) 9 (36.0%) 0.470§ 0.813 0.265–2.495 0.93
Ileocolon
+ 8 (21.6%) 13 (35.1%) 16 (43.2%)
− 11 (61.1%) 4 (22.2%) 3 (16.7%) 0.005§ 5.696 1.667–19.471 0.014
Colon
+ 16 (40.0%) 12 (30.0%) 12 (30.0%)
− 3 (20.0%) 5 (33.3%) 7 (46.7%) 0.142§ 0.375 0.091–1.543 0.33
Complication
Stricturing
+ 6 (25.0%) 8 (33.3%) 10 (41.7%)
− 13 (34.5%) 9 (29.0%) 9 (29.0%) 0.153§ 2.167 0.674–6.962 0.40
Fistulizing
+ 5 (41.7%) 3 (25.0%) 4 (33.3%)
− 14 (32.6%) 14 (32.6%) 15 (34.9%) 0.397§ 0.676 0.182–2.512 0.82
Extraintestinal manifestations
+ 12 (42.9%) 8 (28.6%) 8 (28.6%)
− 7 (25.9%) 9 (33.3%) 11 (40.7%) 0.150§ 0.467 0.149–1.460 0.40
Surgery
+ 4 (23.5%) 3 (17.6%) 10 (58.8%)
− 15 (39.5%) 14 (36.8%) 9 (23.7%) 0.032 5.185 1.114–24.142
* Median age of onset (youngest, oldest); †Logistic regression (age as quantitative variable); ‡Number (%) of patients; §2 testing, A1 + A2 vs.
A0; Unadjusted, A2 vs. A1; OR: odds ratio; CI: confidence interval; ¶2 testing, A0 vs. A1 vs. A2; A0: no mutation; A1: one mutation; A2: two
mutations; +: present, −: not present. Family history: having a first- or second-degree relative with CD; UGT: upper gastrointestinal tract; ileocolon:
terminal ileum or terminal ileum and ascending colon; colon: transverse colon, descending colon, sigmoid, and rectum; surgery: intestinal resection.
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and V793M) found in our patients and those reported in
the literature were all located in or adjacent to the LRRs
region of CARD15 (Fig. 1), indicating a common func-
tional defect (see Introduction).
Another striking difference between our pediatric pa-
tients and those reported in the literature was the much
higher frequency of two mutations in the pediatric group
(35% versus 17%, Table 3). This confirmed that the pa-
tients with early age at disease onset had a greater degree
of genetic influence. However, it was not always pos-
sible to clarify if the two mutations found were located
on one or on two alleles. Homozygous patients clearly
had two affected alleles. We had no cDNA samples
available from patients with two different mutations to
separate the alleles by cloning. Therefore, it can only be
assumed that they were compound heterozygous. At
least, it has already been shown by haplotyping that the
variants R702W, G908R, and 3020insC were never
found on the same haplotype (3).
Consistent with the findings of previous studies (5,11–
14), our results confirmed that there was a strong asso-
ciation between these disease-related mutations and CD
localization in the terminal ileum and ascending colon
(ileocolon, Table 5). It is tempting to hypothesize a con-
nection between this localization at a junction of a sterile
gut region with a region populated with bacteria, com-
ponents of these bacteria such as lipopolysaccharide, and
the mutational alterations in the CARD15 protein re-
sponsible for regulation of inflammation. Stricturing,
which necessitates intestinal resection, is an indication of
a severe clinical course of CD. Such severe disease oc-
curred more frequently in patients with two mutations
(Table 5) than in those with no or one mutation and thus
was more common in pediatric than in adult patients.
The trends we found in clinical associations, which did
not reach significance, were also in accordance with the
findings of others (Table 5) (5,11,12). Younger age at
disease onset and stricturing were associated with
CARD15 mutations, whereas CD localization proximal
to the terminal ileum or distal to the ascending colon and
extraintestinal manifestations may be linked to other IBD
susceptibility genes, e.g. tumor necrosis factor (TNF)-
(-857C) (15).
Future studies are needed to clarify the connection
between functional alterations of proteins involved in
inflammation and different manifestations of CD.
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Note. Lesage et al. (5) studied 453 patients with CD from Europe,
both adults and children were included, but the majority were adults.
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